Hello. Sign In
Standards Store

Desk Reference of Clinical Pharmacology

2007 Edition, October 31, 2007

Complete Document



Detail Summary

Active, Most Current

EN
Additional Comments:
ISBN: 978-1-4200-4743-1
Format
Details
Price (USD)
Print
Backordered
$365.00
Add to Cart

Product Details:

  • Revision: 2007 Edition, October 31, 2007
  • Published Date: October 31, 2007
  • Status: Active, Most Current
  • Document Language: English
  • Published By: CRC Press (CRC)
  • Page Count: 822
  • ANSI Approved: No
  • DoD Adopted: No

Description / Abstract:

PREFACE TO THE SECOND EDITION

Since publication of the first edition of CRC Desk Reference of Clinical Pharmacology in 1998, dramatic discoveries in molecular medicine, along with rapid concomitant technological advances, have revolutionized the diagnosis and treatment of a broad range of human diseases with new medications. Given the rapid pace of new discovery, genetic- and cell-based therapeutics have now become a common part of the physicians' armamentarium . A few examples will be given concerning two leading causes of death—cancer and cardiovascular diseases—to illustrate this.

At the midpoint of the 20th century, our knowledge of cancer was based on epidemiology and pathology, and treatment consisted of surgery and radiation therapy. More modern views on carcinogenesis favor a genetic cause for cancer. The incidence of cancer increases sharply with age, and various models have been proposed to account for this increase. The human immune system can mount a specific response to cancer. Intense research is aimed at dissecting the intricacies of the interaction between the immune system and tumor cells.

A driving force behind this research is the idea that cancer-directed immunity can be enhanced to improve the outcome for patients with the disease. The specificity of the immune response makes cancer immunotherapy extremely effective because it offers the promise of reducing damage to the bystander normal tissues and lessening the severe side effects associated with cancer therapies. Another modern treatment is monoclonal antibodies, which exhibit a favorable pharmacokinetic profile. Pharmacokinetic variability among patients is low, which helps ensure that all patients receiving a given dose achieve appropriate exposure to the drug. Unlike many therapeutics now used in cancer patients, monoclonal antibodies are not subject to metabolic drug–drug interactions and are not substrates of the multidrug-resistant efflux pumps. The third example of emerging molecular therapeutics in cancer patients is drugs interfering with signal transduction pathways. Signal transduction describes the processes involved in the communication between the cell and its environment, and in the regulation of cell fate. These pathways are commonly hijacked by the genomic abnormalities that drive malignant progression. Proof of principle has now been established that targeting signal transduction pathways can be clinically beneficial. Tackling multistep carcinogenesis will most likely require combinatorial therapies: probably cytotoxic plus a signal transduction inhibitor. The fourth example of the molecular therapeutics in cancer patient is suicide gene therapy. The possibility of rendering cancer cells more sensitive to drugs or toxins by introducing suicide genes has two alternatives: toxin gene therapy, in which the genes for toxic products are transformed into tumor cells, and enzyme-activating prodrug therapy, in which the transgene encodes an enzyme that activates specific pro-drugs to create toxic metabolites. The latter approach, as well as suicide gene therapy and gene-directed enzyme prodrug therapy (GDEPT), has also been termed virus-directed enzyme prodrug therapy and gene prodrug activation therapy.

The second edition of the CRC Desk Reference of Clinical Pharmacology is designed specifically for physicians, pharmacists, nurses, and other members of the health care delivery team. It consists of three parts.

Part One: The book still has brief, concise, and informative A–Z drug facts from abciximab to zolpidem tartrate.

Part Two: The book again presents some very novel and exciting entries not seen in any existing textbooks of pharmacology. These items will include, but not be limited to, the items listed below.